Privia Health Group, Inc. (PRVA) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 3, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 6, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the PRVA SEC filings page.
Privia Health Group, Inc. (PRVA) reported $2.4B in revenue over the twelve months to Jun 30, 2026, up 24.1% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Growth is reaching the bottom line and cash flow, but thin margins and a more short-term balance sheet constrain the model.
From FY2023 to FY2025, revenue expanded while operating margin improved only modestly, indicating that scale is producing incremental earnings rather than a dramatic change in profitability. In FY2025, operating cash flow of$163M far exceeded net income of$23M , suggesting cash conversion benefited from balance-sheet movements rather than accounting profit alone.
The company moved from losses in FY2022 to sustained profitability through FY2025, but its latest net margin was only
The current ratio declined from 1.9x in FY2024 to 1.6x in FY2025, narrowing the short-term asset cushion. Current liabilities represented about
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Privia Health Group, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Privia Health Group, Inc. has an operating margin of 1.6%, meaning the company retains $2 of operating profit per $100 of revenue. This results in a moderate score of 32/100, indicating healthy but not exceptional operating efficiency. This is up from 1.0% the prior year.
Privia Health Group, Inc.'s revenue surged 22.3% year-over-year to $2.1B, reflecting rapid business expansion. This strong growth earns a score of 72/100.
Privia Health Group, Inc. has a moderate D/E ratio of 0.78. This balance of debt and equity financing earns a leverage score of 52/100.
Privia Health Group, Inc.'s current ratio of 1.60 indicates adequate short-term liquidity, earning a score of 46/100. The company can meet its near-term obligations, though with limited headroom.
Privia Health Group, Inc.'s ROE of 3.1% shows moderate profitability relative to equity, earning a score of 35/100. This is up from 2.3% the prior year.
Privia Health Group, Inc. scores 4.46, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($2.6B) relative to total liabilities ($578.4M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Privia Health Group, Inc. passes 5 of 7 computable financial strength tests (2 of the nine could not be computed from available data). All 4 profitability signals pass (positive income, cash flow, and earnings quality), no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
For every $1 of reported earnings, Privia Health Group, Inc. generates $7.13 in operating cash flow ($163.4M OCF vs $22.9M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
Key Financial Metrics
Earnings & Revenue
Privia Health Group, Inc. generated $632.6M in revenue in Q2 2026. This represents an increase of 21.4% from the same quarter a year earlier. Against the prior quarter it is up 4.8%.
Privia Health Group, Inc.'s EBITDA was $15.1M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 155.6% from the same quarter a year earlier. Against the prior quarter it is up 41.4%.
Privia Health Group, Inc. reported $9.0M in net income in Q2 2026. This represents an increase of 236.7% from the same quarter a year earlier. Against the prior quarter it is up 195.3%.
Privia Health Group, Inc. earned $0.07 per diluted share (EPS) in Q2 2026. This represents an increase of 250.0% from the same quarter a year earlier. Against the prior quarter it is up 250.0%.
Cash & Balance Sheet
Privia Health Group, Inc. held $412.2M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Not reported for Q2 2026.
Margins & Returns
Privia Health Group, Inc.'s operating margin was 1.9% in Q2 2026, reflecting core business profitability. This is up 1.2 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.6 percentage points.
Privia Health Group, Inc.'s net profit margin was 1.4% in Q2 2026, showing the share of revenue converted to profit. This is up 0.9 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.9 percentage points.
Privia Health Group, Inc.'s ROE was 1.2% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 0.8 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.7 percentage points.
Not reported for Q2 2026.
Capital Allocation
None of these metrics is reported for Q2 2026.
PRVA Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $632.6M+21.4% | $603.8M+25.8% | $541.2M+17.4% | $580.4M+32.5% | $521.2M+23.4% | $480.1M+15.6% | $460.9M+4.6% | $437.9M+4.9% |
| SG&A Expenses | $39.7M+5.7% | $41.5M+30.7% | $29.3M-15.0% | $39.6M+29.1% | $37.5M+29.8% | $31.7M-1.2% | $34.4M+16.3% | $30.7M+12.7% |
| Operating Income | $11.8M+252.9% | $7.4M+42.2% | $11.3M+114.9% | $14.4M+147.8% | $3.3M-34.6% | $5.2M+534.0% | $5.2M+269.6% | $5.8M+5.0% |
| EBITDA | $15.1M+155.6% | $10.7M+50.3% | $13.9M+96.8% | $17.2M+125.6% | $5.9M-14.4% | $7.1M+169.3% | $7.1M+121.8% | $7.6M+4.7% |
| Income Tax | $7.0M+185.7% | $5.6M+166.3% | $2.8M+4.9% | $6.9M+71.7% | $2.5M-28.2% | $2.1M+180.0% | $2.7M+36.6% | $4.0M+60.7% |
| Net Income | $9.0M+236.7% | $3.1M-27.4% | $9.2M+108.0% | $6.9M+94.1% | $2.7M-22.5% | $4.2M+41.4% | $4.4M+55.0% | $3.5M-37.4% |
| EPS (Basic) | $0.07+250.0% | $0.02-33.3% | $0.08+100.0% | $0.06+100.0% | $0.02-33.3% | $0.030.0% | $0.04+33.3% | $0.03-40.0% |
| EPS (Diluted) | $0.07+250.0% | $0.02-33.3% | $0.07+133.3% | $0.05+66.7% | $0.02-33.3% | $0.03+50.0% | $0.03 | $0.03-40.0% |
| Diluted Shares (Avg) | 132M+2.6% | 131M+2.4% | N/A | 129M+2.4% | 128M+2.5% | 128M+2.2% | N/A | 126M+0.7% |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, R&D Expenses, Interest Expense.
PRVA Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.5B+17.0% | $1.4B+19.8% | $1.4B+20.6% | $1.4B+17.9% | $1.3B+18.1% | $1.2B+14.7% | $1.1B+13.6% | $1.1B+15.4% |
| Current Assets | $1.0B+16.1% | $966.0M+9.0% | $911.0M+9.1% | $970.9M+13.7% | $883.0M+13.2% | $886.5M+21.7% | $834.8M+19.1% | $853.8M+22.4% |
| Cash & Equivalents | $412.2M+5.7% | $419.5M-10.6% | $479.7M-2.3% | $441.4M+4.6% | $390.1M+0.7% | $469.3M+33.7% | $491.1M+26.1% | $422.0M+27.7% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Accounts Receivable | $574.2M+29.3% | $513.7M+32.1% | $400.9M+26.8% | $499.0M+22.0% | $444.0M+20.0% | $388.7M+12.3% | $316.2M+8.7% | $409.0M+16.8% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill | $215.8M+25.3% | $209.8M+48.2% | $209.8M+48.2% | $172.2M+23.5% | $172.2M+23.5% | $141.6M+1.5% | $141.6M+2.1% | $139.5M+2.8% |
| Total Liabilities | $650.5M+20.7% | $612.0M+29.1% | $578.4M+27.9% | $588.2M+21.7% | $539.0M+24.2% | $474.0M+16.0% | $452.3M+15.2% | $483.4M+20.5% |
| Current Liabilities | $634.4M+18.6% | $601.3M+27.7% | $568.5M+26.6% | $582.9M+21.6% | $534.9M+24.5% | $470.8M+16.6% | $449.1M+16.1% | $479.5M+21.6% |
| Non-Current Liabilities | $16.1M+287.8% | $10.7M+233.9% | $9.9M+210.8% | $5.3M+35.9% | $4.1M-6.3% | $3.2M-35.5% | $3.2M-42.6% | $3.9M-44.8% |
| Total Equity | $782.3M+14.6% | $753.1M+14.2% | $737.2M+16.1% | $709.1M+15.3% | $682.9M+14.7% | $659.4M+14.3% | $635.2M+13.1% | $614.9M+12.9% |
| Retained Earnings | -$144.2M+16.3% | -$153.2M+12.4% | -$156.3M+12.8% | -$165.5M+9.9% | -$172.3M+7.9% | -$175.0M+8.2% | -$179.2M+7.4% | -$183.6M+6.5% |
Not reported in any period shown, so not listed: Inventory, Long-Term Debt.
PRVA Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $1.1M-86.2% | -$49.5M-105.6% | $127.5M+70.5% | $52.0M+56.8% | $8.0M-76.9% | -$24.1M+27.4% | $74.8M+16.7% | $33.2M+47.6% |
| Depreciation & Amortization | $3.4M+29.9% | $3.3M+72.6% | $2.7M+45.0% | $2.8M+53.9% | $2.6M+42.1% | $1.9M+4.4% | $1.8M+3.4% | $1.8M+3.8% |
| Stock-Based Compensation | $19.4M+2.9% | $21.9M+23.2% | N/A | $19.0M+25.6% | $18.8M+31.0% | $17.8M+49.4% | N/A | $15.1M+39.9% |
| Investing Cash Flow | -$11.5M+87.1% | -$26K | -$91.3M-1357.5% | -$1.2M | -$89.1M | $0+100.0% | -$6.3M-24.7% | $0+100.0% |
| Financing Cash Flow | $3.0M+61.4% | -$10.7M-575.7% | $2.1M+246.5% | $431K-71.1% | $1.9M+7.7% | $2.2M+372.2% | $619K+1373.8% | $1.5M-50.4% |
Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.
PRVA Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | 1.9%+1.2pp | 1.2%+0.1pp | 2.1%+0.9pp | 2.5%+1.1pp | 0.6%-0.6pp | 1.1%+0.9pp | 1.1%+0.8pp | 1.3%0.0pp |
| Net Margin | 1.4%+0.9pp | 0.5%-0.4pp | 1.7%+0.7pp | 1.2%+0.4pp | 0.5%-0.3pp | 0.9%+0.2pp | 0.9%+0.3pp | 0.8%-0.5pp |
| Return on Equity | 1.2%+0.8pp | 0.4%-0.2pp | 1.2%+0.5pp | 1.0%+0.4pp | 0.4%-0.2pp | 0.6%+0.1pp | 0.7%+0.2pp | 0.6%-0.5pp |
| Return on Assets | 0.6%+0.4pp | 0.2%-0.1pp | 0.7%+0.3pp | 0.5%+0.2pp | 0.2%-0.1pp | 0.4%+0.1pp | 0.4%+0.1pp | 0.3%-0.3pp |
| Current Ratio | 1.620.0x | 1.61-0.3x | 1.60-0.3x | 1.67-0.1x | 1.65-0.2x | 1.88+0.1x | 1.860.0x | 1.780.0x |
| Debt-to-Equity | 0.830.0x | 0.81+0.1x | 0.78+0.1x | 0.830.0x | 0.79+0.1x | 0.720.0x | 0.710.0x | 0.790.0x |
| Asset Turnover | 0.420.0x | 0.430.0x | 0.400.0x | 0.430.0x | 0.410.0x | 0.410.0x | 0.410.0x | 0.380.0x |
Not reported in any period shown, so not listed: Gross Margin, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Privia Health Group, Inc. PRVA | FY2025 | $2.1B | $22.9M | 1.1% | $2.6B | 47/100 |
| BrightSpring Health Services, Inc. BTSG | FY2025 | $12.9B | $189.1M | 1.5% | $11.3B | 44/100 |
| Waystar Holding Corp. WAY | FY2025 | $1.1B | $112.1M | 10.2% | $4.9B | 59/100 |
| HealthEquity, Inc HQY | FY2026 | $1.3B | $215.2M | 16.4% | $7.4B | 68/100 |
| Phreesia, Inc. PHR | FY2026 | $480.6M | $2.3M | 0.5% | $643.1M | 45/100 |
Where Privia Health Group, Inc. Ranks
Frequently Asked Questions
What is Privia Health Group, Inc.'s annual revenue?
Privia Health Group, Inc. (PRVA) reported $2.1B in total revenue for fiscal year 2025. This represents a 22.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Privia Health Group, Inc.'s revenue growing?
Privia Health Group, Inc. (PRVA) revenue grew by 22.3% year-over-year, from $1.7B to $2.1B in fiscal year 2025.
Is Privia Health Group, Inc. profitable?
Yes, Privia Health Group, Inc. (PRVA) reported a net income of $22.9M in fiscal year 2025, with a net profit margin of 1.1%.
What is Privia Health Group, Inc.'s EBITDA?
Privia Health Group, Inc. (PRVA) had EBITDA of $44.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Privia Health Group, Inc.'s operating margin?
Privia Health Group, Inc. (PRVA) had an operating margin of 1.6% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Privia Health Group, Inc.'s net profit margin?
Privia Health Group, Inc. (PRVA) had a net profit margin of 1.1% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Privia Health Group, Inc.'s return on equity (ROE)?
Privia Health Group, Inc. (PRVA) has a return on equity of 3.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Privia Health Group, Inc.'s operating cash flow?
Privia Health Group, Inc. (PRVA) generated $163.4M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Privia Health Group, Inc.'s total assets?
Privia Health Group, Inc. (PRVA) had $1.4B in total assets as of fiscal year 2025, including both current and long-term assets.
What is Privia Health Group, Inc.'s current ratio?
Privia Health Group, Inc. (PRVA) had a current ratio of 1.60 as of fiscal year 2025, which is generally considered healthy.
What is Privia Health Group, Inc.'s debt-to-equity ratio?
Privia Health Group, Inc. (PRVA) had a debt-to-equity ratio of 0.78 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Privia Health Group, Inc.'s return on assets (ROA)?
Privia Health Group, Inc. (PRVA) had a return on assets of 1.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Privia Health Group, Inc.'s P/E ratio?
Privia Health Group, Inc. (PRVA) trades at 92.2x earnings, its market capitalization divided by net income of $28.1M net income, trailing 12 months to June 30, 2026. The market capitalization is $2.6B as of Oct 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Privia Health Group, Inc.'s price-to-sales ratio?
Privia Health Group, Inc. (PRVA) trades at 1.1x sales, its market capitalization divided by revenue of $2.4B revenue, trailing 12 months to June 30, 2026. The market capitalization is $2.6B as of Oct 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Privia Health Group, Inc.'s Altman Z-Score?
Privia Health Group, Inc. (PRVA) has an Altman Z-Score of 4.46, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Privia Health Group, Inc.'s Piotroski F-Score?
Privia Health Group, Inc. (PRVA) has a Piotroski F-Score of 5 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Privia Health Group, Inc.'s earnings high quality?
Privia Health Group, Inc. (PRVA) has an earnings quality ratio of 7.13x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Privia Health Group, Inc.?
Privia Health Group, Inc. (PRVA) scores 47 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.